Surface Oncology Highlights New SRF388 Data At AACR Meeting
Surface Oncology Inc (NASDAQ: SURF) announced the presentation of new preclinical and translational data for SRF388, a first-in-class antibody targeting IL-27, at the American Association for Cancer Research (AACR) Annual Meeting 2022.
Benzinga ·
Benzinga
